Site Logo

Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.

“The courage the Sontags have shown not only to battle brain cancer, but to engender a culture of risk taking and innovation to find new tactics to combat this disease is inspiring.”

Ben Deneen, Ph.D. ’11 DSA
Professor, Department of Neurosurgery
Professor, Center for Stem Cells & Regenerative Medicine
Baylor College of Medicine

Why Venture Philanthropy?

We make loans and equity investments to further our mission and expand the impact of our grant making programs. Our goal is to foster the advancement of promising technology by investing in early stage, high-risk/high-reward opportunities to attract financially motivated investors and accelerate the developmental pipeline.

Investment Strategy

We focus our resources solely on opportunities to advance our charitable mission. While we take chances in pursuit of impact, we also seek overall return of principal so we can recycle capital and maximize our long-term effectiveness. Our investments are typically structured as loans and equity investments, and we work with both for-profit and non-profit entities.

Fund Investment Profile

Brand photography for The Sontag Foundation
Areas of Interest

Therapeutics, Diagnostics, Medical Devices & Other Technologies.

Brand photography for The Sontag Foundation
What We Provide

IP Support, Startup Seed Capital, Management Support, & Help Driving Pipeline Expansion/Repurposing.

Brand photography for The Sontag Foundation
Our Difference

Flexible, long-term/patient investments, and access to a network of top investment professionals, clinicians, and researchers.

Portfolio

Kiyatec

Kiyatec is a functional precision oncology company using ex vivo 3D cell culture technology that can be utilized for gliomas in preclinical and clinical settings. This includes providing companies developing therapies an optimized in vitro assessment of drug-on-tumor cell interaction and oncologists with patient-tumor specific responses to therapeutics that could be used to treat gliomas.

Learn More
MimiVax

MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. Their lead product SurVaxM has demonstrated impressive results in early clinical trials and is currently in a Phase 2b clinical study for newly diagnosed glioblastoma.

Learn More
Modifi Bio

Modifi Bio is bypassing the conventional approach of indirectly targeting proteins in cancer cells by developing therapeutics that target cancer through direct DNA modification. Powerful anti-tumor activity has been shown in glioma and other cancer models with intrinsic DNA defects. This approach has the potential to redefine standard of care in glioma and improve treatments across the oncology space.

Learn More
Telo

Telo Therapeutics is developing therapies that could target a wide range of cancers, including patients that have gliomas.

Learn More
AiM Medical Robotics

AiM Medical Robotics is a neurosurgical robotics company that is working to bring high levels of precision, automation, and efficiency, to the complex environment of neurosurgery. This robot has potential applications for brain tumor biopsy, tumor ablation and many other procedures that could impact the health status of brain tumor patients.

Learn More

Contact Sontag Innovation Fund

For all inquiries please contact:

Scott Davis, Ph.D.
Senior Life Sciences Associate
904.273.8755/sdavis@sontagfoundation.org
We are experiencing email issues. If you have not received a response to your email, please contact us via telephone.